Canada: FCA Upholds Ruling That Health Canada Liable For Negligence And Misfeasance In A Public Office

Last Updated: May 9 2017
Article by Devin Doyle

In Apotex Inc. v. Canada, 2017 FCA 73, the Federal Court of Appeal dealt with various appeals from the finding that Health Canada was liable to Apotex for negligence and misfeasance in a public office in their review of Apotex' drug submission for Apo-trazadone.

Apotex filed a submission with Health Canada in 1988 for approval to sell a generic version of the drug trazadone. The submission referenced an allegedly identical US product to rely on bioavailability studies previously used in an American application. Health Canada did not approve the submission and advised that there was a "normal requirement" for a Canadian reference product and that Apotex would need to "conclusively prove" the US product to be identical to the "standard trazadone product marketed in Canada."

After two lawsuits and a settlement agreement with Health Canada's Health Protection Branch (HPB), Apotex received approval in 1995, by which time two generic competitors had already received approval to sell their versions of that drug in Canada. Apotex commenced an action for damages based on multiple causes of action, including negligence, breach of a settlement agreement, misfeasance in public office, and misrepresentation. In a rather scathing decision, the Federal Court found Health Canada liable to Apotex for negligence and because its officials committed the torts of misfeasance in a public office (see our previous post here).

The Trial Judge found that the settlement agreement transformed the relationship between the parties such that the HPB owed Apotex a duty of care. In the settlement agreement, the HPB agreed that it would consider Apotex' submission on the basis of equivalency (i.e. rather than proof that the foreign-sourced reference product, Desyrel, was identical to the Canadian version). Justice Hughes had held that HPB breached the requisite standard of care when officials insisted on assessing Apotex' submission on the standard of identicality, rather than the agreed-upon standard of equivalency. The Trial Judge further found that the HPB ignored the requirements of the settlement agreement, attempted to conceal this from Apotex and was aware that its conduct would likely injure Apotex. This constituted bad faith and the tort of misfeasance in a public office.

Health Canada and Apotex each appealed various aspects of the decision. Health Canada argued that the Trial Judge erred in concluding that a breach of contract could amount to misfeasance. It argued that once the Court found it liable for breach of contract, it was not open to find it liable in misfeasance for the same contract. The FCA disagreed. While a plaintiff cannot be compensated twice for the same loss, Apotex' contract claim was found to be statute barred and there was thus no double compensation. The settlement agreement did not limit Apotex's right to sue in tort. As set out in BG Checo, where conduct prima facie supports an action in contract and in tort, a party may sue in either or both, subject to any limit that the parties have placed on that right in their contract.

Health Canada also argued that the Trial Judge erred in law by finding that the settlement agreement created a relationship of proximity and also by failing to negate any prima facie duty of care based on policy considerations. The FCA again disagreed. The settlement agreement put Apotex in a different relationship with the HPB with respect to the Apo-Trazadone submission. The HPB agreed to review the submission on the standard of equivalency, which was a departure from its usual practice. Both the Trial Judge and FCA held that the HPB does not owe a duty of care to all drug companies with respect to all drug submissions. Thus, whether the imposition of a duty of care would affect the HPB's discretion when it reviews drug submissions was not an issue. The Court of Appeal rejected the argument that imposing a duty of care on the HPB to comply with its agreement would have a chilling effect upon it as regulator. Rather, imposing a duty of care when a government actor chooses to enter into a contract and then breaches the agreement limits the class of claimants and the time in which liability may be affixed. The claimants are confined to those privy to the contract and the claim is subject to the applicable limitation periods. Apotex was entitled to assume that the HPB would carry out the obligation it agreed to.

The FCA also held that it was an error in law for the Trial Judge to find that Apotex failed to mitigate its damages. As the Supreme Court set out in Southcott, a defendant must establish that the plaintiff failed to make reasonable efforts to mitigate the loss. The FCA further held it was an error of law for the Court to dictate a single, reasonable course of action and to fail to consider the reasonableness of Apotex' actual course of conduct, in peculiar circumstances where Apotex was seeking to advance a test case

[180] Thus, in the rather unique circumstances of this case, Apotex' choice to pursue litigation was reasonable. It did not fail to mitigate its loss and it was an error of principle to require Apotex to mitigate its loss by requiring it to abandon its right to have the Health Protection Branch consider evidence to establish the bioequivalence of the Canadian and American reference standards and by requiring Apotex to do the very thing the settlement agreement was intended to avoid: a new bioavailability test using a Canadian reference product.

[181] Had Apotex so proceeded and obtained a notice of compliance, the issuance of the notice of compliance would have rendered moot the issue of the suitability of a foreign reference product. It follows that in any subsequent drug submission the suitability of a foreign reference product would remain a live issue; in the words of the Federal Court, the "battle lines" would be drawn again.

The FCA thus varied the trial judgment to remove the conclusion that Apotex failed to mitigate its loss.

A copy of the judgment can be found here.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.